-
Review
November 7, 2024
- Stem cell exosomes: new hope and future potential for relieving liver fibrosis
- Lihua Li, Yongjie Liu, Kunpeng Wang, et al.
- Clin Mol Hepatol. 2025;31(2):333-349.
- Review
- Stem cell exosomes: new hope and future potential for relieving liver fibrosis
- Lihua Li, Yongjie Liu, Kunpeng Wang, Jinggang Mo, Zhiyong Weng, Hao Jiang, Chong Jin
- Clin Mol Hepatol. 2025;31(2):333-349. Published online November 7, 2024
-
View: 2798 Download: 333 Crossref: 1
- Gut microbiota-mediated gut-liver axis: a breakthrough point for understanding and treating liver cancer
- Chenyang Li, Chujun Cai, Chendong Wang, Xiaoping Chen, Bixiang Zhang, Zhao Huang
- Clin Mol Hepatol. 2025;31(2):350-381. Published online December 11, 2024
-
View: 2230 Download: 245 Crossref: 1
- Original Article
- Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023
- Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed
- Clin Mol Hepatol. 2025;31(2):382-393. Published online November 29, 2024
-
View: 3154 Download: 437 Web of Science: 8 Crossref: 13
- Cost-effectiveness and return on investment of hepatitis C virus elimination in China: A modelling study
- Meiyu Wu, Jing Ma, Xuehong Wang, Sini Li, Chongqing Tan, Ouyang Xie, Andong Li, Aaron G Lim, Xiaomin Wan
- Clin Mol Hepatol. 2025;31(2):394-408. Published online December 3, 2024
-
View: 1687 Download: 160 Crossref: 1
- GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in metabolic dysfunction-associated steatohepatitis livers
- Yi-Tong Li, Wei-Qing Shao, Zhen-Mei Chen, Xiao-Chen Ma, Chen-He Yi, Bao-Rui Tao, Bo Zhang, Yue Ma, Guo Zhang, Rui Zhang, Yan Geng, Jing Lin, Jin-Hong Chen
- Clin Mol Hepatol. 2025;31(2):409-425. Published online December 10, 2024
-
View: 2040 Download: 264 Crossref: 7
- Integrated molecular characterization of sarcomatoid hepatocellular carcinoma
- Rong-Qi Sun, Yu-Hang Ye, Ye Xu, Bo Wang, Si-Yuan Pan, Ning Li, Long Chen, Jing-Yue Pan, Zhi-Qiang Hu, Jia Fan, Zheng-Jun Zhou, Jian Zhou, Cheng-Li Song, Shao-Lai Zhou
- Clin Mol Hepatol. 2025;31(2):426-444. Published online December 10, 2024
-
View: 1804 Download: 151
- Downregulation of the MARC1 p.A165 risk allele reduces hepatocyte lipid content by increasing beta-oxidation
- Ester Ciociola, Tanmoy Dutta, Kavitha Sasidharan, Lohitesh Kovooru, Francesca R. Noto, Grazia Pennisi, Salvatore Petta, Angela Mirarchi, Samantha Maurotti, Bernardette Scopacasa, Luca Tirinato, Patrizio Candeloro, Marcus Henricsson, Daniel Lindén, Oveis Jamialahmadi, Arturo Pujia, Rosellina M. Mancina, Stefano Romeo
- Clin Mol Hepatol. 2025;31(2):445-459. Published online December 23, 2024
-
View: 2488 Download: 336 Crossref: 2
- Longitudinal profile of plasma pregenomic RNA in patients with chronic hepatitis B infection on long-term nucleoside analogues and its interaction with clinical parameters
- Lung-Yi Mak, Mark Anderson, Michael Stec, Matthew Shing-Hin Chung, Danny Ka-Ho Wong, Rex Wan-Hin Hui, Wai-Kay Seto, Gavin Cloherty, Man-Fung Yuen
- Clin Mol Hepatol. 2025;31(2):460-473. Published online December 26, 2024
-
View: 1241 Download: 106
- Prediction of primary biliary cholangitis among health check-up population with anti-mitochondrial M2 antibody positive
- Haolong Li, Song Liu, Xu Wang, Xinxin Feng, Siyu Wang, Yanli Zhang, Fengchun Zhang, Li Wang, Tengda Xu, Yongzhe Li
- Clin Mol Hepatol. 2025;31(2):474-488. Published online December 30, 2024
-
View: 1381 Download: 140 Crossref: 3
- Targeting TM4SF1 promotes tumor senescence enhancing CD8+ T cell cytotoxic function in hepatocellular carcinoma
- Weifeng Zeng, Furong Liu, Yachong Liu, Ze Zhang, Haofan Hu, Shangwu Ning, Hongwei Zhang, Xiaoping Chen, Zhibin Liao, Zhanguo Zhang
- Clin Mol Hepatol. 2025;31(2):489-508. Published online December 30, 2024
-
View: 2378 Download: 304 Crossref: 6
- Male preference for TERT alterations and HBV integration in young-age HBV-related HCC: implications for sex disparity
- Jin Seoub Kim, Hye Seon Kim, Kwon Yong Tak, Ji Won Han, Heechul Nam, Pil Soo Sung, Sung Won Lee, Jung Hyun Kwon, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Jeong Won Jang
- Clin Mol Hepatol. 2025;31(2):509-524. Published online January 2, 2025
-
View: 1504 Download: 123
- Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000–2021
- Pojsakorn Danpanichkul, Luis Antonio Díaz, Kanokphong Suparan, Primrose Tothanarungroj, Supapitch Sirimangklanurak, Thanida Auttapracha, Hanna L. Blaney, Banthoon Sukphutanan, Yanfang Pang, Siwanart Kongarin, Francisco Idalsoaga, Eduardo Fuentes-López, Lorenzo Leggio, Mazen Noureddin, Trenton M. White, Alexandre Louvet, Philippe Mathurin, Rohit Loomba, Patrick S. Kamath, Jürgen Rehm, Jeffrey V. Lazarus, Karn Wijarnpreecha, Juan Pablo Arab
- Clin Mol Hepatol. 2025;31(2):525-547. Published online January 9, 2025
-
View: 3712 Download: 285 Crossref: 7
- Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C
- Tom Ryu, Young Chang, Soung Won Jeong, Jeong-Ju Yoo, Sae Hwan Lee, Sang Gyune Kim, Young Seok Kim, Hong Soo Kim, Seung Up Kim, Jae Young Jang
- Clin Mol Hepatol. 2025;31(2):548-562. Published online January 9, 2025
-
View: 1188 Download: 105 Crossref: 1
- Exploring methylation signatures for high de novo recurrence risk in hepatocellular carcinoma
- Da-Won Kim, Jin Hyun Park, Suk Kyun Hong, Min-Hyeok Jung, Ji-One Pyeon, Jin-Young Lee, Kyung-Suk Suh, Nam-Joon Yi, YoungRok Choi, Kwang-Woong Lee, Young-Joon Kim
- Clin Mol Hepatol. 2025;31(2):563-576. Published online January 13, 2025
-
View: 1239 Download: 87
- Editorial
- From invasive to intuitive: The emerging role of non-invasive models in hepatic decompensation: Editorial on “Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)”
- Akhil Deshmukh, Rakhi Maiwall
- Clin Mol Hepatol. 2025;31(2):577-580. Published online August 19, 2024
-
View: 2141 Download: 37 Crossref: 1
- Challenges and innovations in primary sclerosing cholangitis clinical trials: Evaluating HK-660S and the path forward: Editorial on “Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial”
- Nilanga Nishad
- Clin Mol Hepatol. 2025;31(2):581-583. Published online November 4, 2024
-
View: 796 Download: 38 Crossref: 1
- A novel clinical trial for primary sclerosing cholangitis from Asia: All regional endeavors should improve global management of primary sclerosing cholangitis: Editorial on “Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial”
- Atsumasa Komori
- Clin Mol Hepatol. 2025;31(2):584-588. Published online November 6, 2024
-
View: 934 Download: 44 Crossref: 1
- Intrapatient variability of tacrolimus trough level may be not the cause, but an indirect parameter of comorbidities: Editorial on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”
- Jongman Kim
- Clin Mol Hepatol. 2025;31(2):589-591. Published online January 24, 2025
-
View: 691 Download: 38 Crossref: 1
- Stabilizing hepatic fatty acid oxidation: Editorial on “USP29 alleviates the progression of MASLD by stabilizing ACSL5 through K48 deubiquitination”
- Myeung Gi Choi, Na Young Lee, Ja Hyun Koo
- Clin Mol Hepatol. 2025;31(2):592-595. Published online November 6, 2024
-
View: 1250 Download: 72
- Universal self-testing as a cost-effective weapon to eliminate hepatitis C virus in the Republic of Korea: Editorial on “Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of disease burden and cost-effectiveness”
- Eun Sun Jang
- Clin Mol Hepatol. 2025;31(2):596-598. Published online November 11, 2024
-
View: 798 Download: 22 Crossref: 1
- Circulating cell-free mitochondrial DNA for diagnosing hepatocellular carcinoma and assessing prognosis: Editorial on “Aberrant fragmentomic features of circulating cell-free mitochondrial DNA enable early detection and prognosis prediction of hepatocellular carcinoma”
- Hyuk soo Eun
- Clin Mol Hepatol. 2025;31(2):599-602. Published online December 26, 2024
-
View: 867 Download: 43 Crossref: 2
- Momentum towards simplifying and expanding treatment for chronic hepatitis B: The body of evidence continues to grow: Editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial”
- Robert J. Wong
- Clin Mol Hepatol. 2025;31(2):603-605. Published online October 29, 2024
-
View: 728 Download: 23 Crossref: 1
- Reconsidering treatment indications for chronic hepatitis B: Insights from the TORCH-B roll-over study: Editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial”
- Chih-Wen Wang, Ming-Lung Yu
- Clin Mol Hepatol. 2025;31(2):606-609. Published online December 3, 2024
-
View: 970 Download: 29 Crossref: 1
- A leap in the dark: Bariatric surgery for treatment of metabolic dysfunction-associated steatotic liver disease related cirrhosis: Editorial on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”
- Jing Zeng, Jian-Gao Fan
- Clin Mol Hepatol. 2025;31(2):610-614. Published online December 17, 2024
-
View: 892 Download: 41 Crossref: 2
- Treating systemic inflammation by transjugular intrahepatic portosystemic shunt: Editorial on “Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis”
- Georg Semmler, Lorenz Balcar, Mattias Mandorfer
- Clin Mol Hepatol. 2025;31(2):615-619. Published online January 6, 2025
-
View: 790 Download: 48 Crossref: 2
- Vibration-controlled transient elastography in shaping the epidemiology and management of steatotic liver disease: Editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023”
- Xiao-Dong Zhou, Terry Cheuk-Fung Yip, Daniel Q Huang, Mark Dhinesh Muthiah, Mazen Noureddin, Ming-Hua Zheng
- Clin Mol Hepatol. 2025;31(2):620-624. Published online December 26, 2024
-
View: 1477 Download: 61 Crossref: 2
- Revealing the importance of a multidisciplinary approach to reducing the global burden of SLD through the COVID-19 pandemic: Editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023”
- Jeayeon Park, Su Jong Yu
- Clin Mol Hepatol. 2025;31(2):625-627. Published online January 16, 2025
-
View: 772 Download: 19 Crossref: 2
- Unraveling the role of GOLM1-OPN-ABCG5 axis in MASH: Editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”
- Yoon-su Ha, Won Kim, Seung-Jin Kim
- Clin Mol Hepatol. 2025;31(2):628-630. Published online January 16, 2025
-
View: 1059 Download: 42 Crossref: 2
- Bridging the gap: The GOLM1-OPN-ABCG5 axis in MASH and gallstone disease: Editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”
- Nahee Hwang, Sungsoon Fang
- Clin Mol Hepatol. 2025;31(2):631-634. Published online February 3, 2025
-
View: 912 Download: 44 Crossref: 2
- Genetic insights into sarcomatoid hepatocellular carcinoma: Critical role of ARID2 in pathogenesis and immune feature: Editorial on “Integrated molecular characterization of sarcomatoid hepatocellular carcinoma”
- Naoshi Nishida
- Clin Mol Hepatol. 2025;31(2):635-639. Published online January 24, 2025
-
View: 661 Download: 27 Crossref: 1
- Is AMA M2 a useful serologic test for screening high-risk patients for PBC?: Editorial on “Prediction of primary biliary cholangitis among health check-up population with anti-mitochondrial M2 antibody positive”
- Nae-Yun Heo
- Clin Mol Hepatol. 2025;31(2):640-641. Published online February 13, 2025
-
View: 632 Download: 29 Crossref: 1
- Targeting TM4SF1 to overcome immunotherapy resistance in hepatocellular carcinoma: Editorial on “Targeting TM4SF1 promotes tumor senescence enhancing CD8+ T cell cytotoxic function in hepatocellular carcinoma”
- Valerie Chew
- Clin Mol Hepatol. 2025;31(2):642-645. Published online January 16, 2025
-
View: 834 Download: 47 Crossref: 1
- TM4SF1 - A new immune target for treatment of hepatocellular carcinoma: Editorial on “Targeting TM4SF1 promotes tumor senescence enhancing CD8+ T cell cytotoxic function in hepatocellular carcinoma”
- Chen Rui Yuan, Terence Kin Wah Lee
- Clin Mol Hepatol. 2025;31(2):646-649. Published online February 10, 2025
-
View: 713 Download: 41
- Tetraspan(in)-mediated immune regulation in hepatocellular carcinoma: Editorial on “Targeting TM4SF1 promotes tumor senescence enhancing CD8+ T cell cytotoxic function in hepatocellular carcinoma”
- Seo Hee Jin, Dong Joo Kim, Jung Weon Lee
- Clin Mol Hepatol. 2025;31(2):650-653. Published online February 11, 2025
-
View: 742 Download: 70
- Burden of alcohol use disorder, alcohol-related liver disease, and alcohol-related liver cancer: Editorial on “Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000–2021
- Youxin Wang, Noriko Oza, Jazleen Leo, Ashok Choudhury, Daniel Q. Huang
- Clin Mol Hepatol. 2025;31(2):654-657. Published online February 10, 2025
-
View: 1143 Download: 61 Crossref: 1
- Metabolic dysfunction in patients following DAA-induced viral cure for HCV infection: A non-negligible risk to liver-related health: Editorial on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C”
- Chen-Hua Liu, Yu-Ping Chang
- Clin Mol Hepatol. 2025;31(2):658-661. Published online February 17, 2025
-
View: 650 Download: 39 Crossref: 2
- Screening of patients at high risk of de novo recurrence in HCC: Editorial on “Exploring methylation signatures for high de novo recurrence risk in hepatocellular carcinoma”
- Ping Huang, Shiqiao Luo, Rui Liao
- Clin Mol Hepatol. 2025;31(2):662-664. Published online February 11, 2025
-
View: 605 Download: 31
- Snapshot
- Modulation of lymphatic vessels in management of liver disease and complications
- Aarti Sharma, Pinky Juneja, Shiv K Sarin, Savneet Kaur
- Clin Mol Hepatol. 2025;31(2):665-668. Published online October 17, 2024
-
View: 988 Download: 63 Crossref: 1
- Erratum
- Erratum to ‘Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial’ [Clin Mol Hepatol 2024;30:807-823]
- Sun Young Yim, Sung Hwan Lee, Seung-Woo Baek, Bohwa Sohn, Yun Seong Jeong, Sang-Hee Kang, Kena Park, Hyewon Park, Sunyoung S. Lee, Ahmed O. Kaseb, Young Nyun Park, Sun-Hee Leem, Michael A. Curran, Ji Hoon Kim, Ju-Seog Lee
- Clin Mol Hepatol. 2025;31(2):669-670. Published online February 27, 2025
-
View: 898 Download: 45
- Letter to the Editor
- Letter to the editor on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”
- Hai Xu, Yong Zhou, Huikun Wu
- Clin Mol Hepatol. 2025;31(2):e125-e127. Published online December 17, 2024
-
View: 914 Download: 30 Crossref: 1
- MAFLD or MASLD: Which better represents the prognosis of the steatotic liver population: Letter to the editor on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”
- Ying Wang, Shengfeng Wang, Xiude Fan, Jiajun Zhao, Yongfeng Song
- Clin Mol Hepatol. 2025;31(2):e128-e133. Published online December 26, 2024
-
View: 1207 Download: 74 Crossref: 2
- Global inequality in the burden of hepatitis B from 1990 to 2021: Findings from the global burden of disease study 2021: Letter to the editor on “Comprehensive approach to controlling chronic hepatitis B in China”
- Chunlong Liu, Jiangtao Yu
- Clin Mol Hepatol. 2025;31(2):e134-e136. Published online December 17, 2024
-
View: 1025 Download: 83
- Tacrolimus levels and variability in CKD and ESRD risk post-liver transplant: Letter to the editor on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”
- Rui Shi, Minghua Wang
- Clin Mol Hepatol. 2025;31(2):e137-e139. Published online January 9, 2025
-
View: 726 Download: 41 Crossref: 1
- Treatment response to nucleos(t)ide analogs in chronic hepatitis B with mildly elevated alanine aminotransferase: Letter to the editor on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial”
- Jian Wang, Fei Cao, Chuanwu Zhu, Chao Wu, Rui Huang
- Clin Mol Hepatol. 2025;31(2):e140-e142. Published online December 3, 2024
-
View: 789 Download: 27 Crossref: 1
- Letter to the editor on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”
- Wei Wang, Yating Xie, Ailei Xu
- Clin Mol Hepatol. 2025;31(2):e143-e144. Published online February 18, 2025
-
View: 649 Download: 34
- Prevalence of steatotic liver disease and associated fibrosis in the general population: An epidemiological survey: Letter to the editor on “Epidemiology of metabolic dysfunction-associated steatotic liver disease”
- Lin Guan, Xinhe Zhang, Shanghao Liu, Xiaolong Qi, Yiling Li
- Clin Mol Hepatol. 2025;31(2):e145-e148. Published online October 29, 2024
-
View: 1141 Download: 77
- Correspondence
- Correspondence to letter to the editor on “Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults”
- Chang Hun Lee, In Hee Kim, Sook-Hyang Jeong
- Clin Mol Hepatol. 2025;31(2):e149-e151. Published online November 6, 2024
-
View: 828 Download: 18
- Age serves as the silent architect of FIB-4’s precision in unveiling advanced hepatic fibrosis in MASLD with T2DM: Correspondence to letter to the editor on “Diagnostic accuracy of the fibrosis-4 index for advanced liver fibrosis in nonalcoholic fatty liver disease with type 2 diabetes: a systematic review and meta-analysis”
- Ji Won Han, Dae Won Jun
- Clin Mol Hepatol. 2025;31(2):e152-e154. Published online December 30, 2024
-
View: 900 Download: 30
- Correspondence to editorial on “Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)”
- Chuan Liu, Ling Yang, Hong You, Gao-Jun Teng, Xiaolong Qi
- Clin Mol Hepatol. 2025;31(2):e155-e157. Published online August 30, 2024
-
View: 1058 Download: 45
- Correspondence to editorial on “Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial”
- Woo Hyun Paik, Do Hyun Park
- Clin Mol Hepatol. 2025;31(2):e158-e160. Published online November 11, 2024
-
View: 806 Download: 36
- Correspondence to editorial on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”
- Soon Kyu Lee, Jong Young Choi
- Clin Mol Hepatol. 2025;31(2):e161-e162. Published online February 13, 2025
-
View: 600 Download: 28
- HCV self-testing: Bridging screening gaps and ensuring cost-effectiveness for both high-risk and universal populations: Correspondence to editorial on “Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of disease burden and cost-effectiveness”
- Gyeongseon Shin, Beom Kyung Kim, SeungJin Bae, Hankil Lee, Sang Hoon Ahn
- Clin Mol Hepatol. 2025;31(2):e163-e165. Published online November 29, 2024
-
View: 765 Download: 36
- Correspondence to editorial on “Aberrant fragmentomic features of circulating cell-free mitochondrial DNA enable early detection and prognosis prediction of hepatocellular carcinoma”
- Yang Liu, Fan Peng, Siyuan Wang, Jinliang Xing
- Clin Mol Hepatol. 2025;31(2):e166-e168. Published online January 6, 2025
-
View: 713 Download: 29 Crossref: 1
- Expanding treatment eligibility for chronic hepatitis B: Balancing benefits, limitations, and healthcare access: Correspondence to editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial”
- Yao-Chun Hsu, Chi-Yi Chen, Jaw-Town Lin
- Clin Mol Hepatol. 2025;31(2):e169-e172. Published online December 23, 2024
-
View: 722 Download: 24
- Correspondence to editorial on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”
- Nicholas A. Rouillard, Linda Henry, Mindie H. Nguyen
- Clin Mol Hepatol. 2025;31(2):e173-e175. Published online January 9, 2025
-
View: 765 Download: 29 Crossref: 1
- TIPS insertion and systemic inflammation: Is it ever too late to lower portal pressure? Correspondence to editorial on “Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis”
- Anja Tiede, Benjamin Maasoumy
- Clin Mol Hepatol. 2025;31(2):e176-e179. Published online February 10, 2025
-
View: 679 Download: 18 Crossref: 1
- Addressing the burden of steatotic liver disease: The role of transient elastography: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”
- Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed
- Clin Mol Hepatol. 2025;31(2):e180-e182. Published online February 13, 2025
-
View: 668 Download: 24
- The burden of steatotic liver disease before and during the COVID-19 pandemic: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”
- Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed
- Clin Mol Hepatol. 2025;31(2):e183-e185. Published online February 17, 2025
-
View: 628 Download: 13 Crossref: 1
- Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”
- Yi-Tong Li, Wei-Qing Shao, Zhen-Mei Chen, Jing Lin, Jin-Hong Chen
- Clin Mol Hepatol. 2025;31(2):e186-e188. Published online January 24, 2025
-
View: 658 Download: 36 Crossref: 1
- GOLM1 and bile acid synthesis: Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”
- Yi-Tong Li, Wei-Qing Shao, Zhen-Mei Chen, Jing Lin, Jin-Hong Chen
- Clin Mol Hepatol. 2025;31(2):e189-e191. Published online February 13, 2025
-
View: 671 Download: 29 Crossref: 1
- Correspondence to editorial on “Integrated molecular characterization of sarcomatoid hepatocellular carcinoma”
- Rong-Qi Sun, Shao-Lai Zhou
- Clin Mol Hepatol. 2025;31(2):e192-e193. Published online February 26, 2025
-
View: 592 Download: 21
- Correspondence to editorial on “Prediction of primary biliary cholangitis among health check-up population with anti-mitochondrial M2 antibody positive”
- Haolong Li, Song Liu, Xu Wang, Li Wang, Tengda Xu, Yongzhe Li
- Clin Mol Hepatol. 2025;31(2):e194-e196. Published online February 24, 2025
-
View: 656 Download: 30
- Correspondence to editorial on “Targeting TM4SF1 promotes tumor senescence enhancing CD8+ T cell cytotoxic function in hepatocellular carcinoma”
- Weifeng Zeng, Furong Liu, Yachong Liu, Zhanguo Zhang
- Clin Mol Hepatol. 2025;31(2):e197-e199. Published online February 5, 2025
-
View: 672 Download: 28
- Correspondence to editorial on “Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000-2021”
- Pojsakorn Danpanichkul, Luis Antonio Diaz, Kanokphong Suparan, Karn Wijarnpreecha, Juan Pablo Arab
- Clin Mol Hepatol. 2025;31(2):e200-e202. Published online February 17, 2025
-
View: 778 Download: 30
- Correspondence to editorial on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C”
- Tom Ryu, Young Chang, Seung Up Kim, Jae Young Jang
- Clin Mol Hepatol. 2025;31(2):e203-e205. Published online February 24, 2025
-
View: 504 Download: 17 Crossref: 1
- Correspondence to editorial on “Exploring methylation signatures for high de novo recurrence risk in hepatocellular carcinoma”
- Kwang-Woong Lee, Young-Joon Kim
- Clin Mol Hepatol. 2025;31(2):e206-e207. Published online February 17, 2025
-
View: 606 Download: 21
- Correspondence to letter to the editor 1 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”
- Seogsong Jeong, Won Kim, Sang Min Park
- Clin Mol Hepatol. 2025;31(2):e208-e209. Published online January 6, 2025
-
View: 1005 Download: 22
- Correspondence to letter to the editor 2 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”
- Seogsong Jeong, Won Kim, Sang Min Park
- Clin Mol Hepatol. 2025;31(2):e210-e211. Published online January 6, 2025
-
View: 976 Download: 24
- Correspondence to letter to the editor on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”
- Soon Kyu Lee, Jong Young Choi
- Clin Mol Hepatol. 2025;31(2):e212-e214. Published online February 10, 2025
-
View: 557 Download: 20
- Reply to Correspondence
- Reply to correspondence on “Aberrant fragmentomic features of circulating cell-free mitochondrial DNA enable early detection and prognosis prediction of hepatocellular carcinoma”
- Hyuk Soo Eun
- Clin Mol Hepatol. 2025;31(2):e215-e217. Published online January 16, 2025
-
View: 749 Download: 21
- Reply to correspondence on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”
- Jing Zeng, Jian-Gao Fan
- Clin Mol Hepatol. 2025;31(2):e218-e220. Published online February 3, 2025
-
View: 661 Download: 24
- Reply to correspondence on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”
- Jeayeon Park, Su Jong Yu
- Clin Mol Hepatol. 2025;31(2):e221-e223. Published online March 4, 2025
-
View: 505 Download: 7
- Decreasing systemic inflammation after TIPS: Still hope for the liver: Reply to correspondence on “Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis”
- Georg Semmler, Lorenz Balcar, Mattias Mandorfer
- Clin Mol Hepatol. 2025;31(2):e224-e225. Published online February 17, 2025
-
View: 636 Download: 31
- Reply to correspondence 1 on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”
- Yoon-su Ha, Won Kim, Seung-Jin Kim
- Clin Mol Hepatol. 2025;31(2):e226-e227. Published online February 13, 2025
-
View: 919 Download: 28
- Reply to correspondence 2 on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”
- Nahee Hwang, Sungsoon Fang
- Clin Mol Hepatol. 2025;31(2):e228-e231. Published online February 26, 2025
-
View: 677 Download: 23
- Reply to correspondence on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C”
- Chen-Hua Liu, Yu-Ping Chang
- Clin Mol Hepatol. 2025;31(2):e232-e233. Published online February 26, 2025
-
View: 471 Download: 20
